| Company/Division name | AstraZeneca |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 150 |
| Year reshoring announced: | 2024 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 2,300 |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | Rockville |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell therapy |
| What domestic positive factors made reshoring more attractive? | Infrastructure, Proximity to customers/market, Skilled workforce availability/training |
